Literature DB >> 24390088

Repair of radiation damage of U2OS osteosarcoma cells is related to DNA-dependent protein kinase catalytic subunit (DNA-PKcs) activity.

Xianye Tang1, Feng Yuan, Kaijin Guo.   

Abstract

The present study was to investigate the effects of DNA-PKcs deficiencies on radiation sensitivity of human osteosarcoma U2OS cells to γ-ray and to explore the underlying molecular mechanism. In vitro, U2OS cells were transfected with different DNA-PKcs siRNAs or control siRNAs to establish stably siRNA-transfected cell lines U2OS-Si and U2OS-Sc, respectively. Cell viability and apoptosis after irradiation were analyzed using cell counting kit (CCK-8) and flow cytometric assay, respectively. Expressions of apoptosis-related and oxidative stress-responded proteins were assessed using Western blot. The tumorigenesis activity was examined in nude mice xenograft osteosarcoma mode. Results showed that DNA-PKcs siRNA significantly could inhibit U2OS viability and cell proliferation after exposure to irradiation. Compared with the U2OS and U2OS-Sc cells, the U2OS-Si cells induced higher apoptosis rate and loss of mitochondrial membrane potentials, accompanying with more reactive oxygen species (ROS) and malondialdehyde (MDA) production, increased DNA double-strand breaks (DSBs) induced by irradiation. Protein levels of the anti-apoptotic Bcl-2 were downregulated most obviously in U2OS-Si cells after irradiation, while pro-apoptotic factor Bax and caspase-3 upregulated. Moreover, the antioxidants protein expression levels of Nuclear factor-erythroid 2-related factor 2 (Nrf2) and its target heme oxygenase-1 (HO-1) were also significantly reduced in parallel to DNA-PKcs inhibition in U2OS-Si cells. In nude mice xenograft model, DNA-PKcs siRNA remarkably inhibited tumor growth and dissemination. In conclusion, DNA-PKcs siRNA might have a potential for osteosarcoma treatment by sensitizing osteosarcoma cells to γ-ray through modulation on oxidative stress-mediated DNA DSBs repair and mitochondrial pathway apoptosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24390088     DOI: 10.1007/s11010-013-1955-5

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  32 in total

1.  Effectiveness of radiotherapy for osteosarcoma that responds to chemotherapy.

Authors:  Peter M Anderson
Journal:  Mayo Clin Proc       Date:  2003-02       Impact factor: 7.616

2.  Radiosensitization of breast cancer cells by TRAIL-endostatin-targeting gene therapy.

Authors:  Y B Li; C X Guo; Z C Wang; L H Dong; F Guan; Y Liu; H F Wang; Z W Sun; S L Gong
Journal:  Neoplasma       Date:  2013       Impact factor: 2.575

3.  Neoadjuvant chemotherapy and local radiotherapy for high-grade osteosarcoma of the extremities.

Authors:  Gennady N Machak; Sergey I Tkachev; Yuriy N Solovyev; Pavel A Sinyukov; Stanislav M Ivanov; Natalya V Kochergina; Alexey D Ryjkov; Valery V Tepliakov; Benjamin Y Bokhian; Valeria V Glebovskaya
Journal:  Mayo Clin Proc       Date:  2003-02       Impact factor: 7.616

4.  DNA-PKcs expression predicts response to radiotherapy in prostate cancer.

Authors:  Patrick Bouchaert; Stephane Guerif; Celine Debiais; Jacques Irani; Gaelle Fromont
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-04-09       Impact factor: 7.038

5.  Silencing of DNA-PKcs alters the transcriptional profile of certain signal transduction genes related to proliferation and differentiation in HeLa cells.

Authors:  Jing An; Qin-Zhi Xu; Jian-Li Sui; Bei Bai; Ping-Kun Zhou
Journal:  Int J Mol Med       Date:  2005-09       Impact factor: 4.101

Review 6.  G2 checkpoint abrogators as anticancer drugs.

Authors:  Takumi Kawabe
Journal:  Mol Cancer Ther       Date:  2004-04       Impact factor: 6.261

Review 7.  Bone tumors in adolescents and young adults.

Authors:  Stefan S Bielack; Dorothe Carrle; Jendrik Hardes; Andreas Schuck; Michael Paulussen
Journal:  Curr Treat Options Oncol       Date:  2008-05-01

8.  Oncolytic virus-mediated tumor radiosensitization in mice through DNA-PKcs-specific shRNA.

Authors:  Takashi Kon; Xiuwu Zhang; Qian Huang; Zhonghui Yang; Shanling Liu; Bin Yan; Fang Li; He Wang; Chuan-Yuan Li
Journal:  Transl Cancer Res       Date:  2012-06       Impact factor: 1.241

Review 9.  Cell death regulation by the Bcl-2 protein family in the mitochondria.

Authors:  Yoshihide Tsujimoto
Journal:  J Cell Physiol       Date:  2003-05       Impact factor: 6.384

Review 10.  The Nrf2 system as a potential target for the development of indirect antioxidants.

Authors:  Kyeong-Ah Jung; Mi-Kyoung Kwak
Journal:  Molecules       Date:  2010-10-20       Impact factor: 4.411

View more
  4 in total

1.  Inhibiting DNA-PKCS radiosensitizes human osteosarcoma cells.

Authors:  Tewodros Mamo; Ann C Mladek; Kris L Shogren; Carl Gustafson; Shiv K Gupta; Scott M Riester; Avudaiappan Maran; Mario Galindo; Andre J van Wijnen; Jann N Sarkaria; Michael J Yaszemski
Journal:  Biochem Biophys Res Commun       Date:  2017-03-12       Impact factor: 3.575

2.  The DNA-PK Inhibitor VX-984 Enhances the Radiosensitivity of Glioblastoma Cells Grown In Vitro and as Orthotopic Xenografts.

Authors:  Cindy R Timme; Barbara H Rath; John W O'Neill; Kevin Camphausen; Philip J Tofilon
Journal:  Mol Cancer Ther       Date:  2018-03-16       Impact factor: 6.261

3.  Natural product β-thujaplicin inhibits homologous recombination repair and sensitizes cancer cells to radiation therapy.

Authors:  Lihong Zhang; Yang Peng; Ivan P Uray; Jianfeng Shen; Lulu Wang; Xiangdong Peng; Powel H Brown; Wei Tu; Guang Peng
Journal:  DNA Repair (Amst)       Date:  2017-10-24

4.  Bioengineered NRF2-siRNA Is Effective to Interfere with NRF2 Pathways and Improve Chemosensitivity of Human Cancer Cells.

Authors:  Peng-Cheng Li; Mei-Juan Tu; Pui Yan Ho; Joseph L Jilek; Zhijian Duan; Qian-Yu Zhang; Ai-Xi Yu; Ai-Ming Yu
Journal:  Drug Metab Dispos       Date:  2017-10-23       Impact factor: 3.922

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.